Week of February 28th 2022 | Vol. 11, Issue 9
In This Issue
Upcoming Events
Industry M&A Activity
Recent Transactions
Trading Comps
Market Reports
M&A Pipeline
Featured Headlines
Tanner Updates

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory
Industry Snapshot
Above is an overview of recent industry M&A activity. Click on the chart to download complete transaction tables broken out by industry sub sectors. For additional information, see the Industry M&A Activity section below.
Events Hosted or Attended by Bourne Partners
March 21-24, 2022 - New York City, NY
May 17-19, 2022 - Philadelphia, PA
May 24-26, 2022 - New York City, NY
June 13-16, 2022 - San Diego, CA
October 2022 - Charlotte, NC
INDUSTRY M&A ACTIVITY
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
RECENT TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
M&A TRANSACTIONS
Pharma & Biotech
8 transactions totaling $124 million

Supplies, Equipment & Services
12 transactions totaling $3 million

Healthcare IT & Managed Care
5 transactions totaling $17 million

Healthcare Facilities & Distributors
8 transactions totaling $783 million
PRIVATE PLACEMENTS
Pharma & Biotech
23 transactions totaling $399 million

Supplies, Equipment & Services
22 transactions totaling $833 million

Healthcare IT & Managed Care
16 transactions totaling $430 million

Healthcare Facilities & Distributors
0 transactions
PUBLIC OFFERINGS
Pharma & Biotech
9 transactions totaling $453 million

Supplies, Equipment & Services
9 transactions totaling $1,292 million

Healthcare IT & Managed Care
0 transactions

Healthcare Facilities & Distributors
0 transactions
TRADING COMPS
A Breakdown of Relevant Trading Multiples
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
MARKET REPORTS
Insight Into Healthcare Related Industries
M&A PIPELINE
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
FEATURED HEADLINES
A Sampling of Industry Headlines From Last Week
Russia's invasion of Ukraine is likely to impact millions of people, not just in the Eastern European nation but around the world as drug developers might face delays in clinical trials conducted in Kyiv and elsewhere.

One biotech, in particular, called out the geopolitical tensions as possible cause for concern. Karuna Therapeutics warned today that timelines for its second phase 3 study in schizophrenia, dubbed EMERGENT-3, are uncertain because 10 of the 19 trial sites are in Ukraine.

The study might not be needed for Karuna to file the drug, KarXT, for approval, according to RBC Capital Markets analysts. But, if the first phase 3 trial, EMERGENT-2, fails to meet its primary endpoint and produce safety data, Karuna could be in trouble. EMERGENT-3 is a "backup option," RBC wrote in a Thursday note.
2021 saw a rush of biotechs heading for the public markets, including companies seeking an initial public offering before ever producing a shred of clinical evidence.
February 22, 2022 - Fierce Biotech
The second year of the COVID-19 pandemic saw a wave of global demand for coronavirus tests that finally reached the public markets.
Somatus has secured over $325 million in a series E funding round led by Wellington Management Company, placing the value-based kidney care company at a valuation exceeding $2.5 billion.
For patients with chronic conditions, the battle for their own health can’t be won by visiting the doctor a few times a year, according to Omada Health President Wei-Li Shao.

Discover more about the connection between real-world data capture and early access programs, and the role this plays in the approval of life-improving medicines.